This article draws on available Phase 2 trial data and related incretin therapy experience to provide clear, evidence-informed guidance
The most recent consensus algorithm released by the ADA/EASD lists GLP-1 analogues as a treatment option for consideration as a Tier 2 agent, or less well-validated therapy, in T2DM patients ( FIGURE 1 )
The introduction of N-terminal ketone motifs into genetically encoded materials and their post-translational derivatization provides a paradigm for the programmed synthesis of peptide-derived materials that more closely resemble complex natural products
Implementation: Target: 1.0-1.2 g/kg ideal body weight daily Distribution: 30-40g per meal, 3-4 meals daily Quality: Complete proteins or well-combined plant sources Strategy 4: Electrolyte Vigilance Electrolytes are critical cofactors for the ion pumps and channels involved in the Mitchell mechanism
Additionally, Canadian pharmacies often face the same stock shortages as the US
HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED (IN PIPELINE) TABLE 643 F
